bluebird bio (NASDAQ:BLUE – Get Rating) had its target price trimmed by SVB Leerink from $9.00 to $8.00 in a report published on Monday morning, Benzinga reports. The brokerage currently has a market perform rating on the biotechnology company's stock. SVB Leerink also issued estimates for bluebird bio's Q4 2022 earnings at ($1.18) EPS, FY2022 earnings at ($5.13) EPS, Q1 2023 earnings at ($0.64) EPS, Q2 2023 earnings at ($0.62) EPS, Q3 2023 earnings at ($0.58) EPS, Q4 2023 earnings at ($0.48) EPS, FY2023 earnings at ($2.31) EPS and FY2024 earnings at ($1.59) EPS.
Other equities analysts have also issued reports about the stock. StockNews.com assumed coverage on shares of bluebird bio in a research report on Wednesday, October 12th. They issued a sell rating on the stock. Royal Bank of Canada dropped their price objective on shares of bluebird bio to $8.00 and set a sector perform rating on the stock in a research report on Tuesday, November 8th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, bluebird bio currently has a consensus rating of Hold and an average target price of $6.75.
Get bluebird bio alerts:bluebird bio Trading Down 3.1 %
NASDAQ BLUE opened at $6.33 on Monday. The firm has a market capitalization of $524.90 million, a P/E ratio of -1.04 and a beta of 0.99. The firm's fifty day moving average price is $7.38 and its two-hundred day moving average price is $6.52. bluebird bio has a 1 year low of $2.87 and a 1 year high of $8.58.
bluebird bio (NASDAQ:BLUE – Get Rating) last issued its quarterly earnings data on Monday, November 7th. The biotechnology company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.28) by $0.36. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $2.25 million. bluebird bio had a negative net margin of 8,828.28% and a negative return on equity of 173.58%. On average, research analysts anticipate that bluebird bio will post -4.36 EPS for the current fiscal year.Insider Activity at bluebird bio
In other bluebird bio news, Director Nick Leschly sold 4,290 shares of the stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $7.80, for a total transaction of $33,462.00. Following the sale, the director now directly owns 280,149 shares in the company, valued at $2,185,162.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 9,506 shares of company stock worth $72,088. Corporate insiders own 2.20% of the company's stock.
Institutional Investors Weigh In On bluebird bio
Large investors have recently bought and sold shares of the company. Caxton Associates LP grew its stake in bluebird bio by 559.6% during the second quarter. Caxton Associates LP now owns 220,154 shares of the biotechnology company's stock worth $911,000 after buying an additional 186,778 shares in the last quarter. Virtu Financial LLC bought a new position in shares of bluebird bio in the second quarter worth about $291,000. Monaco Asset Management SAM bought a new position in shares of bluebird bio in the second quarter worth about $1,267,000. WINTON GROUP Ltd bought a new position in shares of bluebird bio in the second quarter worth about $128,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of bluebird bio by 374.8% in the third quarter. Cubist Systematic Strategies LLC now owns 453,763 shares of the biotechnology company's stock worth $2,872,000 after acquiring an additional 358,196 shares during the last quarter. 79.01% of the stock is currently owned by institutional investors and hedge funds.
About bluebird bio
(Get Rating)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
Featured Stories
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.